ribociclib
novartis
['natalee', 'breast', 'novartis']
at #asco23, novartis will present positive data from natalee, our landmark phase iii study evaluating our targeted therapy for a broad population of people diagnosed with hr+/her2- early #breastcancer at risk of recurrence #novartisnews
The official account for @Novartis News & Media Updates. For media inquiries: media.relations@novartis.com. See our community guidelines: https://t.co/b4Kyh4UvNm